Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn's disease

Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn

Authors

  • Matteo Ruggeri ALTEMS - Alta Scuola di Economia e Management dei Sistemi Sanitari, Roma - Italy
  • Michele Basile ALTEMS - Alta Scuola di Economia e Management dei Sistemi Sanitari, Roma - Italy
  • Alessandro Armuzzi Dirigente Medico Medicina Interna e Gastroenterologia, Complesso Integrato Columbus, Policlinico Gemelli, Roma - Italy
  • Americo Cicchetti ALTEMS - Alta Scuola di Economia e Management dei Sistemi Sanitari, Roma - Italy

DOI:

https://doi.org/10.33393/grhta.2017.382

Keywords:

Activity-based costing, Anti-TNF treatments, Crohn's disease, Inflammatory bowel disease, Ulcerative colitis, Vedolizumab

Abstract

Objective To assess the organizational impact of the introduction of vedolizumab compared to the biotechnological anti-TNF alternatives to date available in Italy for the management of Ulcerative Colitis (UC) and Crohn's Disease (CD). Methods A questionnaire aimed at acquiring data about the Italian real practice concerning the management of patients affected by UC and CD was administered to a panel of expert clinicians from three Italian centers of excellence. The determination of the cost of the therapies was realized through an Activity-Based Costing (ABC) analysis which identified the differential between the use of vedolizumab and the alternatives. Results The reduced time of infusion of vedolizumab allows a total cost/infusion of €97.89, with savings vs. infliximab of €39.60 (UC and CD). Vedolizumab implies an expenditure of €17,229.84 (UC) and €17,459.63 (CD) in the first year which allows, compared to Infliximab originator (€17,739.60), a saving/patient of €509.76 and €279.97 for UC and CD respectively. In the following years, vedolizumab implies an expenditure of €13,870.55 and €14,049.95 for UC e CD, lower than infliximab (€14,284.73), with a differential of €414.18 for UC and €234.78 for CD. In the comparison with infliximab biosimilar, the results are the same with regard to the administration costs, but the combined cost administration + drug is lower than that of vedolizumab due to the lower expenditure for drugs. Conclusions Vedolizumab implies a reduction of the time spent by the professionals involved in the provision of the treatment, allowing a reallocation of the saved resources.

Downloads

Published

2017-08-04

How to Cite

1.
Ruggeri M, Basile M, Armuzzi A, Cicchetti A. Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn’s disease: Analisi Organizzativa e di Budget Dell’introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn. Grhta [Internet]. 2017 Aug. 4 [cited 2021 Oct. 15];4(1):88-99. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/382

Issue

Section

Original Research Article

Most read articles by the same author(s)

1 2 > >>